PCA062 in pCAD-positive Tumors.

NCT02375958 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

47

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple Negative Breast Cancer
Head & Neck Cancer
Esophageal Cancer

Interventions

DRUG: PCA062

Sponsor

Novartis Pharmaceuticals